http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-102332035-B1
Outgoing Links
Predicate | Object |
---|---|
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4439 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4439 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P17-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00 |
filingDate | 2018-09-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate | 2021-12-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationDate | 2021-12-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | KR-102332035-B1 |
titleOfInvention | How to reverse the normal aging process and extend lifespan |
abstract | In one aspect, a method of altering programmed cell death comprises administering to a subject in need thereof a therapeutically effective amount of isomyosmin or a pharmaceutically acceptable salt thereof. In other aspects, isomyosmin is administered to treat a wound, hemochromatosis, traumatic brain injury, or a disorder associated with chronic oxidative stress. In other aspects, isomyosmin is administered to increase blood oxygen saturation levels. |
priorityDate | 2017-09-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 833.